Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report
Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with...
Κύριοι συγγραφείς: | Arvin Pramudita, Cleopas M Rumende, Ardi Findyartini |
---|---|
Μορφή: | Άρθρο |
Γλώσσα: | English |
Έκδοση: |
Interna Publishing
2017-04-01
|
Σειρά: | Acta Medica Indonesiana |
Θέματα: | |
Διαθέσιμο Online: | http://www.actamedindones.org/index.php/ijim/article/view/327 |
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Treating more with less: Effectiveness and event outcomes of antituberculosis fixed-dose combination drug versus separate-drug formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for pulmonary tuberculosis patients in real-world clinical practice
ανά: Jacqueline Mui Lan Lai, κ.ά.
Έκδοση: (2019-01-01) -
Relative Bioavailability of Rifampicin in Four Chinese Fixed-dose Combinations Compared with Rifampicin in Free Combinations
ανά: Hui Zhu, κ.ά.
Έκδοση: (2015-01-01) -
Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment
ανά: Jiun-Ting Wu, κ.ά.
Έκδοση: (2015-06-01) -
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis
ανά: Vanessa Albertina Agertt, κ.ά. -
Potential side effects of medicine on patients with tuberculosis fixed-dose combination in dr. Pirngadi Hospital, Medan
ανά: EVA SARTIKA DASOPANG, κ.ά.
Έκδοση: (2020-02-01)